COVID-19 in immunocompromised populations: implications for prognosis and repurposing of immunotherapies
SARS-CoV-2 is the virus responsible for the COVID-19 pandemic. COVID-19 has highly variable disease severity and a bimodal course characterized by acute respiratory viral infection followed by hyperinflammation in a subset of patients with severe disease. This immune dysregulation is characterized b...
Main Authors: | Philip C Robinson, Thomas S Uldrick, Jason D Goldman, Per Ljungman |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2021-06-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Online Access: | https://jitc.bmj.com/content/9/6/e002630.full |
Similar Items
-
Perspectives on COVID-19 and cancer immunotherapy: a review series
by: Paolo Antonio Ascierto, et al.
Published: (2021-03-01) -
Drug Repurposing in the Treatment of COVID-19
by: Mehmet SOYLU, et al.
Published: (2020-12-01) -
Immunotherapy in People With HIV and Cancer
by: Camille E. Puronen, et al.
Published: (2019-08-01) -
Artificial intelligence in COVID-19 drug repurposing
by: Yadi Zhou, PhD, et al.
Published: (2020-12-01) -
Repurposing Orthopaedic Residents Amid COVID-19
by: Omar F. Rahman, MD, MBA, et al.
Published: (2020-06-01)